Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Indivior Pharmaceuticals (INDV) Return on Capital Employed (2023 - 2026)

Indivior Pharmaceuticals has reported Return on Capital Employed over the past 4 years, most recently at 79.29% for Q1 2026.

  • For Q1 2026, Return on Capital Employed rose 7077.0% year-over-year to 79.29%; the TTM value through Mar 2026 reached 79.29%, up 7077.0%, while the annual FY2025 figure was 76.05%, 7980.0% up from the prior year.
  • Return on Capital Employed for Q1 2026 was 79.29% at Indivior Pharmaceuticals, up from 66.41% in the prior quarter.
  • Over five years, Return on Capital Employed peaked at 79.29% in Q1 2026 and troughed at 0.95% in Q4 2023.
  • A 4-year average of 38.42% and a median of 48.4% in 2025 define the central range for Return on Capital Employed.
  • Biggest five-year swings in Return on Capital Employed: soared 696bps in 2024 and later soared 7077bps in 2026.
  • Year by year, Return on Capital Employed stood at 0.95% in 2023, then soared by 730bps to 6.01% in 2024, then surged by 1005bps to 66.41% in 2025, then increased by 19bps to 79.29% in 2026.
  • Business Quant data shows Return on Capital Employed for INDV at 79.29% in Q1 2026, 66.41% in Q4 2025, and 48.4% in Q3 2025.